EVTD Stock Overview
Operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Evotec SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €8.51 |
| 52 Week High | €23.25 |
| 52 Week Low | €8.51 |
| Beta | 1.16 |
| 11 Month Change | -12.72% |
| 3 Month Change | -36.70% |
| 1 Year Change | -60.07% |
| 33 Year Change | -76.77% |
| 5 Year Change | -64.72% |
| Change since IPO | 229.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| EVTD | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | -12.7% | -5.3% | -0.4% |
| 1Y | -60.1% | -40.9% | 6.1% |
Return vs Industry: EVTD underperformed the UK Life Sciences industry which returned -40.9% over the past year.
Return vs Market: EVTD underperformed the UK Market which returned 6.1% over the past year.
Price Volatility
| EVTD volatility | |
|---|---|
| EVTD Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.8% |
Stable Share Price: EVTD's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine EVTD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 5,055 | Mario Polywka | www.evotec.com |
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.
Evotec SE Fundamentals Summary
| EVTD fundamental statistics | |
|---|---|
| Market cap | €1.30b |
| Earnings (TTM) | -€90.69m |
| Revenue (TTM) | €776.60m |
1.7x
P/S Ratio-14.3x
P/E RatioIs EVTD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVTD income statement (TTM) | |
|---|---|
| Revenue | €776.60m |
| Cost of Revenue | €620.02m |
| Gross Profit | €156.57m |
| Other Expenses | €247.26m |
| Earnings | -€90.69m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 06, 2024
| Earnings per share (EPS) | -0.51 |
| Gross Margin | 20.16% |
| Net Profit Margin | -11.68% |
| Debt/Equity Ratio | 56.7% |
How did EVTD perform over the long term?
See historical performance and comparison